Clinical Trials in Palma, Spain
22 recruiting
Showing 1–20 of 45 trials
Recruiting
A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma
Relapsed/Refractory Multiple Myeloma
Janssen Pharmaceutica N.V., Belgium300 enrolled87 locationsNCT05160584
Recruiting
Phase 2Phase 3
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
Lymphatic Malformations
Novartis Pharmaceuticals232 enrolled55 locationsNCT05948943
Recruiting
Phase 3
A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
Relapsed/Refractory Follicular LymphomaRelapsed/Refractory Marginal Zone Lymphoma (R/R MZL)
Regeneron Pharmaceuticals470 enrolled169 locationsNCT06149286
Recruiting
Phase 3
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Non-small Cell Lung CancerAdvanced Non-Small Cell Lung CancerMetastatic Non Small Cell Lung Cancer+3 more
ArriVent BioPharma, Inc.480 enrolled61 locationsNCT07185997
Recruiting
OSIREAL - Osimertinib RWE on EGFRm NSCLC in Spain
Non-small Cell Lung Cancer
AstraZeneca500 enrolled25 locationsNCT06068049
Recruiting
Phase 3
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Relapsed or Refractory Multiple Myeloma
Celgene810 enrolled266 locationsNCT05519085
Recruiting
Phase 3
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Non-small Cell Lung Cancer
Bristol-Myers Squibb1,000 enrolled299 locationsNCT06561386
Recruiting
Phase 3
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Breast NeoplasmsNeoplasm Metastasis
Eli Lilly and Company920 enrolled317 locationsNCT07174336
Recruiting
Phase 3
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Carcinoma, Non-Small Cell Lung
Mirati Therapeutics Inc.630 enrolled351 locationsNCT06875310
Recruiting
Phase 1Phase 2
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
Relapsed/Refractory Systemic Light Chain Amyloidosis
Regeneron Pharmaceuticals220 enrolled19 locationsNCT06292780
Recruiting
Phase 3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Solid TumorsHematologic Malignancies
Merck Sharp & Dohme LLC3,500 enrolled779 locationsNCT03486873
Recruiting
Phase 3
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
Type 1 Diabetes Mellitus
Sanofi723 enrolled141 locationsNCT07088068
Recruiting
Phase 3
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer MetastaticNon-Small-Cell Lung CarcinomaNon-small Cell Carcinoma
Pfizer680 enrolled305 locationsNCT07144280
Recruiting
Phase 3
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
Non-small Cell Lung CancerCarcinoma, Non-Small Cell LungCarcinoma, Non-Small-Cell Lung (NSCLC)
Pfizer714 enrolled329 locationsNCT06758401
Recruiting
Phase 3
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Lung CancerNon-small Cell Lung CancerCarcinoma, Non-Small Cell Lung+3 more
Pfizer1,410 enrolled229 locationsNCT07222566
Recruiting
Phase 3
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Carcinoma, Non-Small Cell LungNeoplasm Metastasis
Eli Lilly and Company1,264 enrolled422 locationsNCT06119581
Recruiting
Phase 3
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Carcinoma, Non-Small Cell Lung
Eli Lilly and Company700 enrolled355 locationsNCT06890598
Recruiting
Phase 3
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
Atherosclerotic Cardiovascular Disease (ASCVD)Elevated Lp(a)
Eli Lilly and Company10,450 enrolled751 locationsNCT07157774
Recruiting
Phase 3
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Metabolic Dysfunction-Associated Steatotic Liver Disease
Eli Lilly and Company4,500 enrolled561 locationsNCT07165028
Recruiting
Phase 3
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
Chronic Kidney DiseaseAtherosclerosis Cardiovascular Disease
Eli Lilly and Company7,140 enrolled568 locationsNCT07241390